What is hiden behind autoinflammation?

Czech version

Authors: Katarína Hrubišková ¹; Miloš Jeseňák ^2,3; Juraj Payer ¹
Authors‘ workplace: Centrum pre periodické horúčky V. internej kliniky LF UK a UN Bratislava, Slovenská republika ¹; Centrum pre periodické horúčky Kliniky detí a dorastu JLF UK a UN Martin, Slovenská republika ²; Centrum pre periodické horúčky Kliniky pneumológie a ftizeológie JLF UK a UN Martin, Slovenská republika ³
Published in: Vnitř Lék 2020; 66(3): 35-43
Category:

Overview

Autoinflammatory diseases represent a group of disorders that are distinct from autoimmune diseases, infections and malignancies. They are characterised by attacks of unprovoked noninfectious inflammation. A key feature of autoinflammatory diseases is dysregulation of innate immune system and overproduction of pro-inflammatory cytokines. The best-characterized group of autoinflammatory diseases arises from mutations in single genes. They are typically manifested by recurrent attacks of fever and serositis as well as arthralgia, myalgia and skin exanthema.

Keywords:

autoinflammatory disease – inflammasome – periodic fever – innate immunity

Sources

1. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133–144.

2. Hoffman HM, Broderick L. The role of the inflammasome in patients with autoinflammatory diseases. J Allergy Clin Immunol 2016; 138: 3–14.

3. Ciccarelli F, De Martinis M, Ginaldi L. An Update on Autoinflammatory Diseases. Current Medicinal Chemistry 201; 21: 261–269.

4. Franceschi C, Bonafe M, Valensin S, et al. Inflamm‑aging. An evolutionary perspective on immunosenescence. Ann NY Acad. Sci USA 2000; 908: 244–254.

5. Ridker PM, et al. CANTOS Trial Group, Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Eng J Med 2017; 377: 1119–1131.

6. Romberg N, Al Moussawi K, Nelson‑Williams C, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 2014; 46: 1135–1139.

7. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PloS Med 2006; 3: e297.

8. Savic S, Dickie LJ, Battelllino M, et al. Familial Mediterranean fever and related periodic fever syndromes.autoinflammatory diseases. Curr Opin Rheumatol 2012; 24: 103–112.

9. Freed D, Stevens EL, Pevsner J. Somatic mosaicism in the human genome. Genes (Basel) 2014; 5: 1064–1094.

10. Tanaka N, Izawa K, Saito MK, et al. High incidence of NLRP3 somatic mosaicism in patient with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum 2011; 63: 3625–3632.

11. Yamin TT, Ayala JM, Miller DK. Activation of the native 45-kDa precursor form of interleukin-1 converting enzyme. J Biol Chem 1996; 271: 13273–13282.

12. Gu Y, Kuida K, Tsutsui H et al. Activation of interferon‑gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997; 275: 206-209.

13. Caryol C, Girard JP. The IL-1 like cytokine IL-33 is inactivated after maturation by capsase-1. Proc Natl Acad Sci USA 2009; 106: 9021–9026.

14. Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol 2006; 8: 1812–1825.

15. Shao W, Yeretssian G, Doiron K et al. The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem 2007; 282: 36321–36329.

16. Gurcel L, Abrami L, Girardin S, et al. Caspase-1 activation of lipid metabolic pathway in response to bacterial pore‑forming toxins promotes cell survival. Cell 2006; 126: 1135–1145.

17. Bergsbaken T, et al. Pyroptosis: Host cell death and inflammation. Nat Rev Microbiol 2009; 7: 99–109.

18. Miao EA, et al. Caspase-1-induced pyroptosis in an innate immune effector mechanism against intracellular bacteria. Nat Immunol 2010; 11: 1136–1142.

19. Pétrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Nature 2007; 14: 1583–1589.

20. Thomas PG, Dash P, Aldridge JR, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009; 30: 566–575.

21. Duncan JA, Gao X, Huang MT, et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC‑containing inflammasome. J Immunol 2009; 182: 6460–6469.

22. Mariathasan S, Newton K, Monack D et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004; 430: 213–218.

23. Martinon F, Pétrilli V, Mayor A, et al. Gout‑associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237–241.

24. Yazdi AS, Guarda G, Riteau N, et al. Nanoparticles activate the NLR pyrin domain con‑ taining 3 (Nlrps3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc Natl Acad Sci USA 2010; 107: 19449–19454.

25. Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. J Clin Invest 2009; 119: 3502-3511.

26. Šedivá A, Horváth R, Maňásek V, et al. Cluster of patients with Familial Mediterranean fever and heterozygous carriers of mutations in MEFV gene in the Czech Republic. Clin Genet 2014; 86: 564–569.

27. Dallos T, Gálová LL, Macejková E, et al. Familial Mediterranean Fever – first experiences in Slovakia. Vnitř Lék 2014; 60: 80–85.

28. Dallos T, Ilenčíková D, Kovács L. Familial Mediterranean Fever – clinical picture, diagno‑ sis and treatment. Vnitř Lék 2014; 60: 30–37.

29. Król P, Doležalová P. Recidivující febrilie u dětí. Pediatr Praxi 2013; 14: 221–224.

30. Sari I, Birlik M, Kasifoglu T. Familial Mediterranean Fever – An updated review. Eur J Rheum 2014; 1: 21–33.

31. Jeseňák M, Hrubišková K, Kapustová L, et al. Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region. Bratisl Med J 2018; 119: 198–200.

32. Drewe E, et al. Prospective study of anti‑tumour necrosis factor superfamily 1 B fusion protein, and case study of anti‑tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology 2003; 42: 235–239.

33. Nigrovic PA. Cryopyrin‑Associated periodic syndromes and related disorders. www. uptodate.com, 2016

34. Majeed HA, Kalaawi M, Mohanty D, et al. Congenital dyserythropoietic anemia and chronic reccurent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. J Pediatr 1989; 115: 730–734.

35. Cheung MS, Theodoropoulou K, Lugrin J, et al. Periodic Fever with Aphtous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome Is Associated with CARD8 Variant Unable To Bind the NLRP3 Inflammasome. J Immunol 2017; 198: 2063–2069.

36. Marshall GS, Edwards KM, Lawton AR PFAPA syndrome. Pediatr Infect Dis J 1989; 8: 658–659.

37. Thomas KT, Feder HM, Lawton AR, et al. Periodic fever syndrome in children. J Pediatr 1999; 135: 15–21.

38. Hofer M, Cochard M, Anton J, et al. PFAPA (periodic fever, oral aphtae, pharyngitis and cervical adenitis) syndrome: a new consensus on diagnostic criteria. Ann Rheum Dis 2009; 68: (Suppl. 3): 705.

39. Jeseňák M, Kapustová L, Škereňová M, et al. PFAPA syndróm a klinický imunológ. Klinická imunológia a alergológia 2016; 3: 11–15.

40. Federici S, Sormani MP, Ozen S, et al. Evidence‑based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 2015; 74: 799.

41. Cuisset L, Jeru I, Dumont B, et al. Mutation in the autoinflammatory cryopyrin‑associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis 2011; 70: 495.

42. Toplak N, Doležalová P, Constantin T, et al. Periodic Fever syndromes in Eastern and Central European countries: result of a pediatric multinational survey. Pediatric Rheumatology 2010; 8: 29.

43. Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis 2012; 71: 1177–1182.

44. Shinar, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis 2012; 71: 1599–1605.